A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Phase 2b Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects with Active Psoriatic Arthritis

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Phase 2b Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects with Active Psoriatic Arthritis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Jul 2018

At a glance

  • Drugs Tildrakizumab (Primary)
  • Indications Psoriatic arthritis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Sun Pharma Global FZE
  • Most Recent Events

    • 16 Feb 2018 Planned End Date changed from 1 Sep 2019 to 15 May 2020.
    • 16 Feb 2018 Planned primary completion date changed from 1 Sep 2019 to 15 Jan 2020.
    • 16 Feb 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top